MDCK-MRP2 - Dkfz

Forschungsschwerpunkt E
Innovative Krebsdiagnostik und -therapie
[7] *Aimová D., *Dlouhá, Frei E., Stiborová M.: Anticancer drug
ellipticine acts as an inducer of CYP1A1/2 and potentiates its own
pharmacological efficiency. In: Cytochromes P450, Biochemistry,
Biophysics and Drug Metabolism, P. Anzenbacher, J. Hudecek
eds. Manduzzi Editore, Bologna, (2003) 133-138.
[8] Stiborová M., Breuer A., *Aimová D., *Stiborová-Rupertová
M., Wiessler M., Frei E.: DNA adduct formation by the anticancer
drug ellipticine in rats determined by ³²P postlabeling. Int. J.
Cancer 107 (2003) 885-890.
[9] Stiborová M., Frei E.: Utilization of cytochromes P450 to explain
a new mode of action of anticancer drug ellipticine. In: Cytochromes
P450, Biochemistry, Biophysics and Drug Metabolism,
P. Anzenbacher, J. Hudecek eds. Manduzzi Editore, Bologna,
(2003) 99-105.
[10] Frei E., Bieler C. A., *Arlt V. M., Wiessler M., Stiborová M.:
Covalent binding of the anticancer drug ellipticine to DNA in V79
cells transfected with human cytochrome P450 enzymes.
Biochem. Pharmacol. 64 (2002) 289-295.
[11] Borek-Dohalska L., Frei E., Stiborová M.: DNA adduct formation
by the anticancer drug ellipticine and its hydroxy derivatives
in human breast adenocarcinoma MCF-7 cells. Collect. Czech.
Chem. Commun. 69 (2004) 603-615.
[12] Raddatz S., Marcello M., Kliem H.-C., Tröster H.,
Trendelenburg M. F., Oeser T., Granzow C., Wiessler M.: Synthesis
of new boron-rich building blocks for boron neutron capture
therapy or energy-filtering transmission electron microscopy.
ChemBioChem 5 (2004) 474-482.
[13] Wiessler M., Sauerbrei B., Kliem H.-C., Schmauser B.:
Verfahren zur Herstellung von wasserlöslichen Saccharidkonjugaten
durch Diels-Alder-Reaktion und ihre Verwendung als Therapeutika
oder Diagnostika. Patent Deutschland Nr.22.8.2000 100
41 221.1.
[14] Wiessler M.: Biologische Abbaubarkeit als Kriterium bei der
Wirkstoffentwicklung. In: Spurenstoffe in Gewässern, T. Track,
G. Kreysa, Wiley-VCH (2003) 133-144.
[15] Dollner R., Granzow C., *Helmke B., Ruess A., *Schad A.,
*Dietz A.: The impact of stromal cell contamination on chemosensitivity
testing of head and neck carcinoma. Anticancer Research
24 (2004) 325-332.
[16] Dollner R., Granzow C, *Werner J. A., *Dietz A.: Is there a
role for chemosensitivity tests in head and neck cancer?
Onkologie 27 (2004) 310-315.
[17] Granzow C., Kopun-Granzow M., Ponstingl H., Gros G., Hefft
I., Stöhr M.: Pharmazeutische Zusammensetzung zur Aufhebung
der membranvermittelten Resistenz von Zellen, US-Patent
6,376,224 (23. 4. 2002), Europäisches Patent 0967997 (19. 11.
2003)
Abteilung E080
Molekulare Toxikologie
DKFZ 2004: Wissenschaftlicher Ergebnisbericht 2002 - 2003
339